<p>Embecta（納斯達克代碼：EMBC）總裁兼首席執行官 Devdatt Kurdikar 表示，該公司最近在美國的業務重組反映了客户特定的市場份額損失、市場趨勢疲軟和庫存相關因素的綜合影響，同時強調這家糖尿病設備製造商正在繼續實施更廣泛的多元化戰略，旨在減少對其核心胰島素注射業務的依賴。</p>
<p>在美國銀行的一次活動上，Kurdikar 將公司最近的一個季度——Embecta 的財政第二季度和日曆第一季度——形容為 “無疑是一個具有挑戰性的季度”。他説，美國業務大約佔 Embecta 全球業務的一半，在公司分拆後，儘管經歷了與 COVID 相關的干擾和通貨膨脹壓力，但這一業務在多年內一直保持穩定。</p>
<p>他説，這種情況在最新的季度發生了變化，因為多個因素匯聚在一起，導致財政 2026 年的指導下調。</p>
<h2>美國重組受市場份額損失、市場疲軟和庫存驅動</h2>
<p>Kurdikar 表示，Embecta 在一家大型美國零售商那裏失去了市場份額，儘管其產品仍然可以通過該客户獲得。他説，該公司在該零售商的排名從第一位降至第二位。</p>
<p>“在這種情況下，我會説最大的因素是價格，” Kurdikar 説，並補充説問題不在於產品質量，Embecta 也不認為更廣泛的競爭格局發生了實質性變化。</p>
<p>他説，市場份額損失對收入的影響與銷量不成比例，因為受影響的患者可能在報銷多種產品的支付計劃中，而這些計劃的回扣低於優先或獨佔計劃。</p>
<p>Kurdikar 還指出，胰島素筆處方的疲軟，Embecta 將其視為領先指標。他表示，胰島素筆處方在很長一段時間內保持穩定，但最近顯示出下降的跡象，尤其是在零售方面。他説，長效胰島素的下降比速效胰島素更為明顯，新處方也可見下降。</p>
<p>其他因素包括批發商尋求更高效率的庫存調整、注射器的長期下降回歸，以及公司決定在全球範圍內停止棉籤的生產。Kurdikar 表示，棉籤的利潤相對較低，Embecta 未能找到合格的活性成分供應商。</p>
<h2>公司關注 GLP-1、保險變化和零售趨勢</h2>
<p>Kurdikar 表示，Embecta 仍在評估最近的市場疲軟是暫時的還是結構性的。他説，公司在過去幾周內看到客户特定市場份額損失的穩定，但需要更多關於胰島素筆處方趨勢的數據。</p>
<p>他説，Embecta 正在考慮市場疲軟的幾種可能解釋，包括 GLP-1 藥物的可負擔性提高和《平價醫療法案》補貼的到期。Kurdikar 指出，泵的採用率穩步上升，但表示他沒有看到泵採用的突然加速跡象。</p>
<p>根據 Kurdikar 的説法，如果患者失去保險，他們可能會繼續通過低成本選項使用胰島素，但可能會從零售筆針轉向低成本的現金支付、私人品牌或在線替代品。他表示，這可能有助於解釋為什麼零售筆針的下降似乎大於零售胰島素筆的下降。</p>
<p>他還表示，GLP-1 的可負擔性在去年日曆年末有所改善，可能加速了 GLP-1 的使用，而新的胰島素啓動則有所減弱。Kurdikar 警告説，Embecta 只有大約三個月的數據，並表示公司在其指導中假設當前條件將持續到今年剩餘時間。</p>
<h2>多元化戰略仍然是核心</h2>
<p>Kurdikar 表示，公司當前的戰略可以追溯到大約 18 個月前決定終止其貼片泵項目、專注於減少債務並追求多元化。他説，Embecta 開始開發新的筆針和新的注射器，以向面臨價格壓力的客户提供低價替代品。</p>
<p>新的注射器已在中國首次商業銷售，新的筆針正在美國、巴西和歐洲的 CE 標誌進行監管審查，Kurdikar 説。</p>
<p>Embecta 還在建立與仿製 GLP-1 藥物相關的 B2B 渠道。Kurdikar 表示，在大約 30 家仿製藥公司合作伙伴中，40% 選擇了 Embecta 作為供應商。他説，印度的仿製藥推出大多與 Embecta 的筆針共同包裝，兩家合作伙伴已在加拿大獲得批准，巴西可能在今年內發生。中國可能在明年，他説。</p>
<p>Kurdikar 表示，公司之前將與 GLP-1 相關的 B2B 機會描述為至少 1 億美元，並且在過去一年中，這一機會顯得 “越來越真實”。</p>
<h2>Owen Mumford 交易預計將加速轉型</h2>
<p>Kurdikar 表示，Embecta 對即將進行的 Owen Mumford 交易感到興奮，他將其描述為擴展胰島素注射輸送到更廣泛的醫療設備和藥物輸送平台的一種方式。</p>
<p>他説，Owen Mumford 帶來了主要在歐洲和美國部分地區銷售的醫療設備，而 Embecta 則擁有全球商業基礎設施，特別是在拉丁美洲和亞洲。Kurdikar 表示，Embecta 計劃通過自己的商業渠道將 Owen Mumford 的醫療設備組合全球化。</p>
<p>他還強調了 Owen Mumford 的藥物輸送能力，包括自動注射器和可重複使用的筆注射器，並表示收購的業務為製藥公司開發了定製的自動注射器。該交易包括 1 億美元的預付款和 5000 萬美元的里程碑付款，後者與新產品相關。</p>
<p>Kurdikar 表示，Embecta 並未對有意義的製造成本協同效應進行建模，僅包含了一小部分運營費用協同效應。他提到，潛在的機會包括製造網絡優化、後台整合、物流節省和分銷效率。</p>
<h2>現金流、債務償還和資本配置</h2>
<p>儘管指導方針進行了調整，Kurdikar 表示，Embecta 仍預計今年將產生約 1 億美元的自由現金流。他表示，這一數字包括大約 4000 萬美元的一次性成本，其中約 3000 萬美元與公司的品牌轉型相關。</p>
<p>他還討論了 Embecta 最近的資本配置變化，包括將季度股息從每股 0.15 美元減少至 0.01 美元，並獲得董事會批准的 1 億美元為期三年的股票回購授權。</p>
<p>Kurdikar 表示，這一變化為 Embecta 提供了在股票回購和債務償還之間靈活運用自由現金流的空間，他將這兩項視為自由現金的主要用途。展望未來，他表示公司不會提供 2027 財年的指導，但指出可能影響未來現金流的因素，包括 Owen Mumford 的收入、GLP-1 B2B 的增長、新的筆針、新的注射器、整合成本以及與自動注射器平台相關的可能的或有支付。</p>
<p>Kurdikar 表示，困難的季度並未導致 Embecta 偏離其戰略。“我們仍然相信這是正確的戰略，” 他説，並補充説 Owen Mumford 的收購預計將有助於加速公司的轉型。</p>
<h2>關於 Embecta NASDAQ: EMBC</h2>
<p>Embecta Corp NASDAQ: EMBC 是一家專注於糖尿病護理的純粹公司，於 2021 年 7 月 1 日從 Becton, Dickinson and Company 分拆而出。總部位於新澤西州富蘭克林湖，Embecta 專注於開發、製造和商業化能夠為糖尿病患者提供胰島素輸送和血糖監測的產品。</p>
<p>該公司的產品組合包括胰島素輸注裝置、耐用和貼片泵、筆針、輸注管、血糖測試條、採血針和採血設備。</p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何疑問或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Embecta 嗎？</h2>
<p>在考慮 Embecta 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Embecta 並不在名單上。</p>
<p>雖然 Embecta 目前在分析師中獲得了減持評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>查看這五隻股票</p>

EMBC

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

<p>Embecta 的首席執行官 Devdatt Kurdikar 宣佈，由於市場份額下降、市場疲軟和庫存問題，公司將在美國進行業務重組，這將影響 2026 財年的指導。該公司正在多元化發展，超越胰島素注射，開發新產品，並探索 GLP-1 藥物的機會。Kurdikar 強調了最近與 Owen Mumford 達成的交易對擴展其醫療設備平台的重要性。儘管面臨挑戰，但市場份額下降的穩定跡象和對市場狀況的持續評估仍在進行中</p>

<p>Embecta NASDAQ: EMBC President and CEO Devdatt Kurdikar said the company’s recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and inventory-related factors, while emphasizing that the diabetes device maker is continuing a broader diversification strategy intended to make the business less dependent on its core insulin injection franchise.</p>
<div class="lb-trans"><p>Embecta（納斯達克代碼：EMBC）總裁兼首席執行官 Devdatt Kurdikar 表示，該公司最近在美國的業務重組反映了客户特定的市場份額損失、市場趨勢疲軟和庫存相關因素的綜合影響，同時強調這家糖尿病設備製造商正在繼續實施更廣泛的多元化戰略，旨在減少對其核心胰島素注射業務的依賴。</p>
</div><p>Speaking at a Bank of America event, Kurdikar described the company’s most recent quarter — Embecta’s fiscal second quarter and calendar first quarter — as “unquestionably a challenging quarter.” He said the U.S. business, which represents about half of Embecta’s global business, had been stable for years following the company’s spinout, even through COVID-related disruptions and inflationary pressures.</p>
<div class="lb-trans"><p>在美國銀行的一次活動上，Kurdikar 將公司最近的一個季度——Embecta 的財政第二季度和日曆第一季度——形容為 “無疑是一個具有挑戰性的季度”。他説，美國業務大約佔 Embecta 全球業務的一半，在公司分拆後，儘管經歷了與 COVID 相關的干擾和通貨膨脹壓力，但這一業務在多年內一直保持穩定。</p>
</div><p>That changed in the latest quarter, he said, as several factors converged and contributed to a reduction in fiscal 2026 guidance.</p>
<div class="lb-trans"><p>他説，這種情況在最新的季度發生了變化，因為多個因素匯聚在一起，導致財政 2026 年的指導下調。</p>
</div><h2>U.S. Reset Driven by Share Loss, Market Softness and Inventory</h2>
<div class="lb-trans"><h2>美國重組受市場份額損失、市場疲軟和庫存驅動</h2>
</div><p>Kurdikar said Embecta lost share with one large U.S. retailer, though its products remain available through that customer. He said the company moved from the No. 1 position to the No. 2 position at that retailer.</p>
<div class="lb-trans"><p>Kurdikar 表示，Embecta 在一家大型美國零售商那裏失去了市場份額，儘管其產品仍然可以通過該客户獲得。他説，該公司在該零售商的排名從第一位降至第二位。</p>
</div><p>“In this particular case, I would say the single largest factor was price,” Kurdikar said, adding that the issue was not product quality and that Embecta does not believe the broader competitive landscape has changed materially.</p>
<div class="lb-trans"><p>“在這種情況下，我會説最大的因素是價格，” Kurdikar 説，並補充説問題不在於產品質量，Embecta 也不認為更廣泛的競爭格局發生了實質性變化。</p>
</div><p>He said the revenue impact from the share loss was disproportionate to volume because the affected patients were likely on payer plans that reimburse a range of products, where rebates are lower than on preferred or exclusive plans.</p>
<div class="lb-trans"><p>他説，市場份額損失對收入的影響與銷量不成比例，因為受影響的患者可能在報銷多種產品的支付計劃中，而這些計劃的回扣低於優先或獨佔計劃。</p>
</div><p>Kurdikar also pointed to softness in insulin pen prescriptions, which Embecta tracks as a leading indicator. He said insulin pen prescriptions had been stable for a long period but recently showed signs of decline, particularly in retail. The decline was more pronounced in long-acting insulin than fast-acting insulin and was also visible in new prescriptions, he said.</p>
<div class="lb-trans"><p>Kurdikar 還指出，胰島素筆處方的疲軟，Embecta 將其視為領先指標。他表示，胰島素筆處方在很長一段時間內保持穩定，但最近顯示出下降的跡象，尤其是在零售方面。他説，長效胰島素的下降比速效胰島素更為明顯，新處方也可見下降。</p>
</div><p>Other factors included inventory adjustments as wholesalers seek greater efficiency, a return to the long-term decline in syringes and the company’s decision to discontinue swabs globally. Kurdikar said swabs were a comparatively low-margin product and Embecta was unable to find a qualified supplier for an active ingredient.</p>
<div class="lb-trans"><p>其他因素包括批發商尋求更高效率的庫存調整、注射器的長期下降回歸，以及公司決定在全球範圍內停止棉籤的生產。Kurdikar 表示，棉籤的利潤相對較低，Embecta 未能找到合格的活性成分供應商。</p>
</div><h2>Company Watching GLP-1s, Insurance Changes and Retail Trends</h2>
<div class="lb-trans"><h2>公司關注 GLP-1、保險變化和零售趨勢</h2>
</div><p>Kurdikar said Embecta is still assessing whether the recent market softness is temporary or structural. He said the company has seen stabilization in the customer-specific share loss over the past several weeks, but needs more data on insulin pen prescription trends.</p>
<div class="lb-trans"><p>Kurdikar 表示，Embecta 仍在評估最近的市場疲軟是暫時的還是結構性的。他説，公司在過去幾周內看到客户特定市場份額損失的穩定，但需要更多關於胰島素筆處方趨勢的數據。</p>
</div><p>He said Embecta is considering several possible explanations for market softness, including increased affordability of GLP-1 drugs and the expiration of ACA subsidies. Kurdikar noted that pump adoption has been rising steadily, but said he has not seen signs of a sudden acceleration in pump adoption.</p>
<div class="lb-trans"><p>他説，Embecta 正在考慮市場疲軟的幾種可能解釋，包括 GLP-1 藥物的可負擔性提高和《平價醫療法案》補貼的到期。Kurdikar 指出，泵的採用率穩步上升，但表示他沒有看到泵採用的突然加速跡象。</p>
</div><p>According to Kurdikar, if patients lose insurance, they may continue taking insulin through lower-cost options but may switch away from retail pen needles to lower-cost cash-pay, private-label or online alternatives. He said that could help explain why retail pen needle declines appear greater than retail insulin pen declines.</p>
<div class="lb-trans"><p>根據 Kurdikar 的説法，如果患者失去保險，他們可能會繼續通過低成本選項使用胰島素，但可能會從零售筆針轉向低成本的現金支付、私人品牌或在線替代品。他表示，這可能有助於解釋為什麼零售筆針的下降似乎大於零售胰島素筆的下降。</p>
</div><p>He also said GLP-1 affordability improved late last calendar year, potentially accelerating GLP-1 uptake while new insulin starts have softened. Kurdikar cautioned that Embecta has only about three months of data and said the company assumed in its guidance that current conditions persist through the rest of the year.</p>
<div class="lb-trans"><p>他還表示，GLP-1 的可負擔性在去年日曆年末有所改善，可能加速了 GLP-1 的使用，而新的胰島素啓動則有所減弱。Kurdikar 警告説，Embecta 只有大約三個月的數據，並表示公司在其指導中假設當前條件將持續到今年剩餘時間。</p>
</div><h2>Diversification Strategy Remains Central</h2>
<div class="lb-trans"><h2>多元化戰略仍然是核心</h2>
</div><p>Kurdikar said the company’s current strategy dates back to its decision about 18 months ago to terminate its patch pump program, focus on debt reduction and pursue diversification. He said Embecta began developing a new pen needle and a new syringe to offer lower-priced alternatives to customers facing pricing pressure.</p>
<div class="lb-trans"><p>Kurdikar 表示，公司當前的戰略可以追溯到大約 18 個月前決定終止其貼片泵項目、專注於減少債務並追求多元化。他説，Embecta 開始開發新的筆針和新的注射器，以向面臨價格壓力的客户提供低價替代品。</p>
</div><p>The new syringe has had its first commercial sale in China, and the new pen needle is under regulatory review in the U.S., Brazil and for CE mark in Europe, Kurdikar said.</p>
<div class="lb-trans"><p>新的注射器已在中國首次商業銷售，新的筆針正在美國、巴西和歐洲的 CE 標誌進行監管審查，Kurdikar 説。</p>
</div><p>Embecta is also building a business-to-business channel tied to generic GLP-1 drugs. Kurdikar said that of roughly 30 generic drug company partners Embecta is speaking with, 40% have chosen Embecta as a supplier. He said generic launches in India are largely co-packaged with Embecta pen needles, two partners have received approvals in Canada and Brazil could still occur this year. China is likely next year, he said.</p>
<div class="lb-trans"><p>Embecta 還在建立與仿製 GLP-1 藥物相關的 B2B 渠道。Kurdikar 表示，在大約 30 家仿製藥公司合作伙伴中，40% 選擇了 Embecta 作為供應商。他説，印度的仿製藥推出大多與 Embecta 的筆針共同包裝，兩家合作伙伴已在加拿大獲得批准，巴西可能在今年內發生。中國可能在明年，他説。</p>
</div><p>Kurdikar said the company previously described the GLP-1-related B2B opportunity as at least $100 million and that, over the past year, the opportunity has appeared “more and more real.”</p>
<div class="lb-trans"><p>Kurdikar 表示，公司之前將與 GLP-1 相關的 B2B 機會描述為至少 1 億美元，並且在過去一年中，這一機會顯得 “越來越真實”。</p>
</div><h2>Owen Mumford Deal Expected to Accelerate Transformation</h2>
<div class="lb-trans"><h2>Owen Mumford 交易預計將加速轉型</h2>
</div><p>Kurdikar said Embecta is excited about its pending Owen Mumford transaction, which he described as a way to expand beyond insulin injection delivery into a broader medical device and drug delivery platform.</p>
<div class="lb-trans"><p>Kurdikar 表示，Embecta 對即將進行的 Owen Mumford 交易感到興奮，他將其描述為擴展胰島素注射輸送到更廣泛的醫療設備和藥物輸送平台的一種方式。</p>
</div><p>He said Owen Mumford brings medical devices sold primarily in parts of Europe and the U.S., while Embecta has global commercial infrastructure, particularly in Latin America and Asia. Kurdikar said Embecta plans to globalize Owen Mumford’s medical device portfolio through its own commercial channels.</p>
<div class="lb-trans"><p>他説，Owen Mumford 帶來了主要在歐洲和美國部分地區銷售的醫療設備，而 Embecta 則擁有全球商業基礎設施，特別是在拉丁美洲和亞洲。Kurdikar 表示，Embecta 計劃通過自己的商業渠道將 Owen Mumford 的醫療設備組合全球化。</p>
</div><p>He also highlighted Owen Mumford’s drug delivery capabilities, including autoinjectors and reusable pen injectors, and said the acquired business has developed bespoke autoinjectors for pharmaceutical companies. The transaction includes $100 million upfront and $50 million contingent on milestones tied to a new product, he said.</p>
<div class="lb-trans"><p>他還強調了 Owen Mumford 的藥物輸送能力，包括自動注射器和可重複使用的筆注射器，並表示收購的業務為製藥公司開發了定製的自動注射器。該交易包括 1 億美元的預付款和 5000 萬美元的里程碑付款，後者與新產品相關。</p>
</div><p>Kurdikar said Embecta did not model meaningful manufacturing cost synergies and only included a modest amount of operating expense synergies. Potential opportunities include manufacturing network optimization, back-office rationalization, logistics savings and distribution efficiencies, he said.</p>
<div class="lb-trans"><p>Kurdikar 表示，Embecta 並未對有意義的製造成本協同效應進行建模，僅包含了一小部分運營費用協同效應。他提到，潛在的機會包括製造網絡優化、後台整合、物流節省和分銷效率。</p>
</div><h2>Cash Flow, Debt Paydown and Capital Allocation</h2>
<div class="lb-trans"><h2>現金流、債務償還和資本配置</h2>
</div><p>Despite the guidance reset, Kurdikar said Embecta still expects about $100 million in free cash flow this year. He said that figure includes roughly $40 million in one-time costs, including about $30 million tied to the company’s brand transition.</p>
<div class="lb-trans"><p>儘管指導方針進行了調整，Kurdikar 表示，Embecta 仍預計今年將產生約 1 億美元的自由現金流。他表示，這一數字包括大約 4000 萬美元的一次性成本，其中約 3000 萬美元與公司的品牌轉型相關。</p>
</div><p>He also discussed Embecta’s recent capital allocation changes, including reducing its quarterly dividend from $0.15 per share to $0.01 per share and obtaining a $100 million, three-year share repurchase authorization from the board.</p>
<div class="lb-trans"><p>他還討論了 Embecta 最近的資本配置變化，包括將季度股息從每股 0.15 美元減少至 0.01 美元，並獲得董事會批准的 1 億美元為期三年的股票回購授權。</p>
</div><p>Kurdikar said the change gives Embecta flexibility to deploy free cash flow between share repurchases and debt repayment, which he described as the two primary uses of free cash. Looking ahead, he said the company is not providing fiscal 2027 guidance but pointed to factors that could affect future cash flow, including Owen Mumford revenue, GLP-1 B2B growth, new pen needles, new syringes, integration costs and possible contingent payments tied to the autoinjector platform.</p>
<div class="lb-trans"><p>Kurdikar 表示，這一變化為 Embecta 提供了在股票回購和債務償還之間靈活運用自由現金流的空間，他將這兩項視為自由現金的主要用途。展望未來，他表示公司不會提供 2027 財年的指導，但指出可能影響未來現金流的因素，包括 Owen Mumford 的收入、GLP-1 B2B 的增長、新的筆針、新的注射器、整合成本以及與自動注射器平台相關的可能的或有支付。</p>
</div><p>Kurdikar said the difficult quarter is not causing Embecta to deviate from its strategy. “We still believe that’s the right strategy,” he said, adding that the Owen Mumford acquisition is expected to help accelerate the company’s transformation.</p>
<div class="lb-trans"><p>Kurdikar 表示，困難的季度並未導致 Embecta 偏離其戰略。“我們仍然相信這是正確的戰略，” 他説，並補充説 Owen Mumford 的收購預計將有助於加速公司的轉型。</p>
</div><h2>About Embecta NASDAQ: EMBC</h2>
<div class="lb-trans"><h2>關於 Embecta NASDAQ: EMBC</h2>
</div><p>Embecta Corp NASDAQ: EMBC is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.</p>
<div class="lb-trans"><p>Embecta Corp NASDAQ: EMBC 是一家專注於糖尿病護理的純粹公司，於 2021 年 7 月 1 日從 Becton, Dickinson and Company 分拆而出。總部位於新澤西州富蘭克林湖，Embecta 專注於開發、製造和商業化能夠為糖尿病患者提供胰島素輸送和血糖監測的產品。</p>
</div><p>The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.</p>
<div class="lb-trans"><p>該公司的產品組合包括胰島素輸注裝置、耐用和貼片泵、筆針、輸注管、血糖測試條、採血針和採血設備。</p>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何疑問或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Embecta Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Embecta 嗎？</h2>
</div><p>Before you consider Embecta, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Embecta 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Embecta wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Embecta 並不在名單上。</p>
</div><p>While Embecta currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Embecta 目前在分析師中獲得了減持評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Embecta Faces U.S. Reset as CEO Bets on GLP-1, Owen Mumford Diversification

Market Beat

Embecta

美國銀行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Embecta 面臨美國市場重組，CEO 押注 GLP-1，Owen Mumford 尋求多元化發展